The angiogenic polypeptide heparin
Heparin-binding growth factor (HBGF)-1 and HBGF-2, also commonly characterized as acidic and basic fibroblast growth factor, respectively, are structurally related members of the HBGF family of proteins (reviewed in refs. 1 and 2). Numerous biological properties of HBGF-1 and HBGF-2 indicate that they could play an important role in the pathogenesis of certain vascular diseases (reviewed in ref. 3) . For example, smooth muscle cell migration and proliferation occurs during atherogenesis (reviewed in ref. 4) . HBGF-1 is a chemotactic factor (5) and both polypeptides are mitogenic (6) for smooth muscle cells cultured in vitro. Also, the administration of HBGF-2 after balloon catheter injury of the rat carotid artery induces smooth muscle cell proliferation and intimal thickening (7) . Another process in which the two HBGFs may be involved is the neovascularization of atherosclerotic plaques (8) . Both polypeptides stimulate endothelial cell proliferation and migration in vitro (9) (10) (11) and induce angiogenesis in vivo (9, 12) .
Vascular endothelial and smooth muscle cells not only respond to HBGF-1 and HBGF-2 but may be sources for these polypeptides in vivo. Human and bovine endothelial and smooth muscle cells cultured in vitro express HBGF-2 (13) (14) (15) (16) . HBGF-1 mRNA is present in both human endothelial and smooth muscle cells, but the expression level is significantly higher in smooth muscle cells (refs. 16 and 17; unpublished data). HBGF-1 and HBGF-2 are also expressed by vascular cells in vivo. The mRNAs encoding both HBGFs are present in rat aortic tissue (18) ; in addition, immunoreactive HBGF-2 protein has been detected in medial smooth muscle cells of rat arteries (19) . Although these results suggest that vessel wall-derived HBGF-1 and HBGF-2 could stimulate vascular cell proliferation by both autocrine and paracrine mechanisms, it should be noted that neither protein contains a hydrophobic signal peptide required for secretion via the classical secretory pathway. Therefore, they may not normally exit the cell; in this case, autocrine effects could only occur if they act intracellularly or if they were released as a result of sublethal cell damage. Paracrine stimulation of neighboring cells could only occur if the HBGFs were released via cell injury or lysis. Alternatively, the two HBGFs may be actively released from cells by an unknown secretory mechanism. This possibility is supported by studies demonstrating that HBGF-2-specific neutralizing antibodies inhibit the basal growth (20) (21) (22) and migration (20) of bovine endothelial cells.
As an approach to identify factors that may modulate HBGF-1 and HBGF-2 production by vascular cells in vivo, we are investigating the regulation of HBGF gene expression by using smooth muscle cells cultured in vitro. Previous studies have indicated that HBGF-2 mRNA levels increase after serum stimulation of quiescent human foreskin fibroblasts (23) and after phorbol ester treatment of human umbilical vein endothelial cells (24) . Serum and phorbol ester also induce HBGF-2 gene expression in human astrocytoma cells (25, 26) . In this report, we demonstrate that the multifunctional cytokine interleukin (IL)-1 can induce HBGF-2 gene expression in human vascular smooth muscle cells and skin fibroblasts.
MATERIALS AND METHODS
Cell Culture. Human aortic and saphenous vein smooth muscle cells were generously supplied by P. Libby (27) and were rendered quiescent by incubation for 24 hr in 0.5% serum-containing medium without HBGF-1. RNA Gel Blot Analysis. For the experiment reported in Fig.  LA , quiescent cells were treated with recombinant human IL-la (10 ng/ml), IL-1f (10 ng/ml), IL-6 (40 ng/ml), or tumor necrosis factor (TNF)-a (20 ng/ml), which were obtained from Genzyme. For all additional experiments, cells were treated with recombinant human IL-la kindly provided by P. Lomedico (Hoffmann-La Roche). In the IL-la antibody neutralization experiments, cells were treated for 4 hr with IL-la (1 ng/ml) that had been incubated for 16 hr at 40C in either phosphate-buffered saline (Mediatech), phosphatebuffered saline containing 1 mg of nonimmune rabbit IgG (Sigma), or phosphate-buffered saline containing 1 mg of rabbit anti-human IL-la polyclonal antibody (Genzyme). Cycloheximide (10 pg/ml; Sigma), actinomycin D (2 pg/ml; Calbiochem), dexamethasone (2 AM; Sigma), hydrocortisope (200 AM; Sigma), and recombinant human interferon (IFN)-y (50 ng/ml; Boehringer Mannheim) were also used for some RNA gel blot experiments. Cells were harvested, total RNA was prepared as described (17) , and 10 pug ofeach sample was denatured and subjected to electrophoresis in 1.2% agarose gels containing 2.2 M formaldehyde. The gels were stained with ethidium bromide to verify that each lane contained similar amounts of undegraded ribosomal RNA. RNA was electroblotted onto Zetabind nylon membranes (AMF Cuno) and cross-linked by UV irradiation using a Stratalinker (Stratagene). The restriction fragments used and the source of DNA probes were as follows: (i) bovine HBGF-2, 1.4-kilobase (kb) EcoRI fragment of pJJ11-1 (gift of J. Abraham, California Biotechnology, Mountain View, CA); (ii) human IL-183, 0.7-kb EcoRI/Nde I fragment of pAliB (gift of U. Gubler, Hoffmann-La Roche); (iii) human glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 0.8-kb Pst I/Xba I fragment of pHcGAP (American Type Culture Collection). The probes .were labeled to high specific activity with
[12P]dCTP (3000 Ci/mmol; 1 Ci = 37 GBq; Amersham) using a random primer labeling kit (Boehringer Mannheim). Hybridization and membrane washing conditions were as described (27) . Blots were exposed to film (XAR-5; Kodak) with an intensifying screen at -800C. Autoradiographic signals were quantitated with an LKB laser densitometer; the degree of HBGF-2 mRNA induction was calculated after normalization to GAPDH mRNA levels.
Immunoprecipitation Analysis. HSVSMCs were incubated for 72 hr in standard medium containing 0.5% fetal bovine serum, and an equivalent number of cells either were left untreated or were treated with IL-la (10 ng/ml) for 2 hr. The cells were rinsed twice with serum-free/cysteine-free medium and then incubated for 6.5 hr in this medium with or without IL-la. The medium contained 250 'Ci of [35S]cysteine per ml (1200 Ci/mmol; Amersham) during the last 6 hr of this incubation. The cells were then washed twice with cold Hanks' balanced salt solution (GIBCO), harvested by gently scraping the flasks with a rubber policeman, and solubilized in a modified RIPA buffer [20 mM 3-(Nmorpholino)propanesulfonic acid/150 mM NaCl/1 mM EDTA/1% Nonidet P-40/1% deoxycholate/0.1% SDSJ containing phenylmethylsulfonyl fluoride (174 pg/nml; Sigma), leupeptin (0.5 pg/ml; Sigma), and aprotinin (2 pg/ml; Boeh- with recombinant IL-la, IL-1p, IL-6, or TNF-a. RNA was prepared and HBGF mRNA levels were assayed by RNA gel blot hybridization analysis. IL-1.3 mRNA expression was also examined as a positive control for IL-1 and TNF-a activity, and in this and all other RNA analyses we controlled for RNA loading by rehybridization to a GAPDH probe. HBGF-1 transcripts of the appropriate size (17) were expressed at a similar level in both quiescent and cytokinetreated HSVSMCs (data not shown). In contrast, IL-la, IL-1f3, and TNF-a increased HBGF-2 mRNA levels; as estimated by densitometry, the amount of HBGF-2 mRNA was increased 4.5-fold by both IL-1 polypeptides and 1.3-fold by TNF-a (Fig. LA) . Our size estimates for the major HBGF-2 mRNAs in HSVSMCs (7.0 and 3.7 kb) agree with those reported for other cell types (13) (14) (15) . Three smallersized transcripts can also be detected by using longer film exposures and have been reported by others (23, 24, 26) . Since we have not observed differential regulation of these various transcripts, only the major mRNA species are shown in the figures. IL-1 and TNF-a also increased IL-1(3 mRNA levels, although detection of the TNF-a-induced IL-1f3 transcripts required longer film exposures than the one presented here. Our estimated sizes for the IL-1(3 and GAPDH mRNAs, 1.6 and 1.3 kb, respectively, also agree with those reported previously (31, 33) . At the concentration used and at the time point examined, IL-6 did not increase HBGF-2 or IL-1p gene expression.
We focused our subsequent studies on the regulation of HBGF-2 gene expression by IL-la, and for comparison we also analyzed IL-la-induced IL-1f3 gene expression. IL-1 caused a concentration-dependent increase in HBGF-2 mRNA levels; induction was apparent at 0.25 ng/ml, the lowest concentration tested (data not shown). Since endotoxin treatment of HSVSMCs can induce IL-1,B gene expression (34), we determined whether the increased HBGF-2 and IL-13 mRNA levels observed after IL-1 treatment were due to contaminating endotoxin in our recombinant IL-1 preparation. Two experimental approaches indicated that this was not the case. First, the lipopolysaccharide antagonist polymyxin B did not prevent IL-i-induced HBGF-2 or IL-1,B (10 ng/ml), IL-6 (40 ng/ml), or TNF-a (20 ng/ml). RNA was prepared, and equivalent amounts of each sample were used for RNA gel blot analysis. In this and subsequent RNA gel blot figures, the cDNA probes used are indicated on the left, and the upper and lower tick marks on the left side of each HBGF-2 blot represent the positions of 28S and 18S rRNA, respectively. After obtaining optimal film exposures, the HBGF-2 blots were rehybridized to the GAPDH probe. (B) Quiescent HSVSMCs either were left untreated (NT) or were treated for 4 hr with IL-la (1 ng/ml), IL-la (1 ng/ml) preincubated with nonimmune (NI) rabbit IgG, or IL-la (1 ng/ml) preincubated with rabbit anti-human IL-la antibody. RNA was prepared, and equivalent amounts ofeach sample were used for RNA gel blot analysis.
mRNA expression (data not shown). Second, pretreatment of IL-1 with anti-IL-i IgG, but not nonimmune IgG, blocked the ability of our IL-1 preparation to increase HBGF-2 and IL-1i3 mRNA levels (Fig; 1B) .
IL-1 Induction of HIBGF-2 mRNA Expression Does Not Occur if Transcription Is Inhibited and May Require de Novo
Protein Synthesis. The kinetics of HBGF-2 mRNA induction were investigated by RNA gel blot analysis using RNA prepared from HSVSMCs treated with IL-1 for different periods of time. Increased HBGF-2 mRNA levels were evident 1 hr after IL-1 addition and peak expression was from 2 to 4 hr ( Fig. 2A) . At 10 hr poststimulation, the level of HBGF-2 mRNA was still above that observed in quiescent cells. Similar kinetics were observed for IL-1i/ mRNA expression and agree with the results reported by Warner et al. (31) .
To determine whether de novo protein synthesis was required for HBGF-2 mRNA accumulation after IL-1 treatment, quiescent HSVSMCs were stimulated with IL-1 for 4 hr in the absence or presence of cycloheximide, an inhibitor of translation elongation. RNA was prepared and used in RNA gel blot hybridization experiments. HBGF-2 mRNA levels increased in response to the addition of IL-1 and cycloheximide together, although the level obtained was similar to that observed when cycloheximide alone was added (Fig. 2B ). This result is in contrast to the effect of cycloheximide on IL-i-induced IL-1ip gene expression. Cycloheximide alone had only a small effect on IL-l, mRNA levels, and treatment with both IL-1 and cycloheximide "superinduced" IL-1p mRNA levels. Similar cycloheximide effects on IL-1i mRNA induction have been observed in endotoxin-treated HSVSMCs (34) . These HSVSMCs synthesized a polypeptide of -18 k-Da that was immunoprecipitated specifically by this antibody (Fig. 3) (28, 29) , expressed increased levels of HBGF-2 mRNA after IL-1 treatment. Quiescent HSVSMCs LUO Z + ++ z -J *J * and aortic smooth muscle cells either were left untreated or were treated for 4 hr with an equivalent amount ofIL-1. RNA was prepared and used for RNA gel blot analysis. Smooth muscle cells isolated by enzymatic dissociation from human aorta or from explants of saphenous vein showed a similar response to IL-1 (Fig. 5) .
We then investigated whether the effect of IL-1 on HBGF-2 gene expression was cell type specific. For this analysis, we used two cell types that respond differently to IL-1 treatment. IL-1 is mitogenic for human fibroblasts (46, 47) but inhibits endothelial cell proliferation (47, 48) . Quiescent human skin fibroblasts and umbilical vein endothelial cells either were left untreated or were treated for 4 hr with an equivalent amount of IL-1. RNA was prepared and used for RNA gel blot analysis. IL-1 was able to induce both HBGF-2 and IL-1f3 gene expression in human skin fibroblasts (Fig. 5) . In contrast, IL-1 treatment of human umbilical vein endothelial cells did not increase HBGF-2 mRNA levels, although IL-1f3 gene expression was induced. A similar result was obtained by using human aortic endothelial cells (data not shown). In contrast to the other cell types tested, we could detect IL-1/3 mRNA in untreated endothelial cells.
Also, the largest HBGF-2 transcript expressed in human umbilical vein endothelial cells was -6.4 kb, smaller than the 7.0-kb mRNA detected in the other cell types.
In conclusion, the results described above demonstrate that IL-1 can regulate HBGF-2 gene expression in smooth muscle cells and fibroblasts cultured in vitro. HBGF-2 is a potent mitogen for many cell types and an angiogenic factor. Thus, increased production of HBGF-2 in response to IL-1 in vivo may play a role in the pathogenesis of numerous diseases, including Kaposi's sarcoma, rheumatoid arthritis, and atherosclerosis. In regard to vascular pathology, leukocyte migration into the vessel wall occurs after vascular injury and during early stages of atherogenesis (reviewed in refs. 49 and 50). Indeed, a large proportion ofthe cells in human advanced atherosclerotic plaques are monocyte-derived macrophages and T lymphocytes (51, 52) . IL-1 released from these cell types could induce additional IL-1 production by vascular endothelial (37) and smooth muscle (31) We thank Drs. P. Libby and M. Gimbrone for their generous gifts of vascular cell cultures, P. Lomedico for the IL-lca, U. Gubler for the IL-1, cDNA clone, and J. Abraham for the HBGF-2 cDNA clone. We also thank P. Donohue and K. Peifley for technical assistance; K. Wawzinski and S. Young for secretarial assistance; and Drs. T. Maciag, W. Burgess, and T. Hla for critical review of the manuscript. C.G.G. performed this work in partial fulfillment of the requirements for the PhD degree from the Department of Microbiology, George Washington University School of Medicine, Washington, DC. This research was supported in part by National Institutes of Health Grant HL39727 (to J.A;W.).
